vs
PHIBRO ANIMAL HEALTH CORP（PAHC）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
PHIBRO ANIMAL HEALTH CORP的季度营收约是BRC Group Holdings, Inc.的2.0倍（$373.9M vs $188.3M），BRC Group Holdings, Inc.净利率更高（47.9% vs 7.3%，领先40.6%），PHIBRO ANIMAL HEALTH CORP同比增速更快（20.9% vs -21.9%），过去两年PHIBRO ANIMAL HEALTH CORP的营收复合增速更高（19.2% vs -15.4%）
菲宝罗动物保健公司是一家美国动物健康与矿物质营养企业，主营产品涵盖抗菌药、抗球虫药、驱虫药，以及畜禽营养补充剂、疫苗等。公司下设矿物质营养、功能材料、动物健康三大业务板块，收入主要来源于上述板块，业务遍及美国、拉美、加拿大、欧洲、中东、非洲及亚太地区。
PAHC vs RILY — 直观对比
营收规模更大
PAHC
是对方的2.0倍
$188.3M
营收增速更快
PAHC
高出42.8%
-21.9%
净利率更高
RILY
高出40.6%
7.3%
两年增速更快
PAHC
近两年复合增速
-15.4%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $373.9M | $188.3M |
| 净利润 | $27.5M | $90.3M |
| 毛利率 | 35.5% | 79.5% |
| 营业利润率 | 13.5% | 32.3% |
| 净利率 | 7.3% | 47.9% |
| 营收同比 | 20.9% | -21.9% |
| 净利润同比 | 762.1% | 1710.8% |
| 每股收益（稀释后） | $0.67 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PAHCRILY
| Q4 25 | $373.9M | $188.3M | ||
| Q3 25 | $363.9M | $215.3M | ||
| Q2 25 | $378.7M | $188.2M | ||
| Q1 25 | $347.8M | $197.2M | ||
| Q4 24 | $309.3M | $241.0M | ||
| Q3 24 | $260.4M | $225.5M | ||
| Q2 24 | $273.2M | $256.0M | ||
| Q1 24 | $263.2M | $263.4M |
净利润PAHCRILY
| Q4 25 | $27.5M | $90.3M | ||
| Q3 25 | $26.5M | $91.1M | ||
| Q2 25 | $17.2M | $139.5M | ||
| Q1 25 | $20.9M | $-10.0M | ||
| Q4 24 | $3.2M | $-5.6M | ||
| Q3 24 | $7.0M | $-284.4M | ||
| Q2 24 | $752.0K | $-433.6M | ||
| Q1 24 | $8.4M | $-49.2M |
毛利率PAHCRILY
| Q4 25 | 35.5% | 79.5% | ||
| Q3 25 | 32.9% | 83.7% | ||
| Q2 25 | 29.0% | 81.3% | ||
| Q1 25 | 30.1% | 81.4% | ||
| Q4 24 | 32.9% | 79.8% | ||
| Q3 24 | 32.1% | 82.1% | ||
| Q2 24 | 31.9% | 84.5% | ||
| Q1 24 | 30.2% | 85.3% |
营业利润率PAHCRILY
| Q4 25 | 13.5% | 32.3% | ||
| Q3 25 | 14.1% | 30.4% | ||
| Q2 25 | 8.9% | 5.7% | ||
| Q1 25 | 9.6% | -31.2% | ||
| Q4 24 | 8.3% | -69.2% | ||
| Q3 24 | 6.8% | -36.4% | ||
| Q2 24 | 6.7% | -90.8% | ||
| Q1 24 | 7.6% | -6.1% |
净利率PAHCRILY
| Q4 25 | 7.3% | 47.9% | ||
| Q3 25 | 7.3% | 42.3% | ||
| Q2 25 | 4.5% | 74.1% | ||
| Q1 25 | 6.0% | -5.1% | ||
| Q4 24 | 1.0% | -2.3% | ||
| Q3 24 | 2.7% | -126.1% | ||
| Q2 24 | 0.3% | -169.4% | ||
| Q1 24 | 3.2% | -18.7% |
每股收益（稀释后）PAHCRILY
| Q4 25 | $0.67 | $2.78 | ||
| Q3 25 | $0.65 | $2.91 | ||
| Q2 25 | $0.43 | $4.50 | ||
| Q1 25 | $0.51 | $-0.39 | ||
| Q4 24 | $0.08 | $-0.01 | ||
| Q3 24 | $0.17 | $-9.39 | ||
| Q2 24 | $0.02 | $-14.35 | ||
| Q1 24 | $0.21 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.5M | $226.6M |
| 总债务越低越好 | $624.2M | $1.4B |
| 股东权益账面价值 | $332.4M | $-171.5M |
| 总资产 | $1.4B | $1.7B |
| 负债/权益比越低杠杆越低 | 1.88× | — |
8季度趋势，按日历期对齐
现金及短期投资PAHCRILY
| Q4 25 | $74.5M | $226.6M | ||
| Q3 25 | $85.3M | $184.2M | ||
| Q2 25 | $77.0M | $267.4M | ||
| Q1 25 | $70.4M | $138.3M | ||
| Q4 24 | $67.1M | $146.9M | ||
| Q3 24 | $89.8M | $159.2M | ||
| Q2 24 | $114.6M | $236.9M | ||
| Q1 24 | $98.7M | $190.7M |
总债务PAHCRILY
| Q4 25 | $624.2M | $1.4B | ||
| Q3 25 | $628.0M | $1.3B | ||
| Q2 25 | $631.7M | $1.3B | ||
| Q1 25 | $635.4M | $1.4B | ||
| Q4 24 | $639.1M | $1.5B | ||
| Q3 24 | $295.2M | — | ||
| Q2 24 | $312.1M | — | ||
| Q1 24 | — | — |
股东权益PAHCRILY
| Q4 25 | $332.4M | $-171.5M | ||
| Q3 25 | $311.7M | $-260.5M | ||
| Q2 25 | $285.7M | $-351.7M | ||
| Q1 25 | $266.0M | $-496.8M | ||
| Q4 24 | $246.8M | $-488.2M | ||
| Q3 24 | $258.5M | $-497.6M | ||
| Q2 24 | $256.6M | $-218.3M | ||
| Q1 24 | $270.1M | $228.4M |
总资产PAHCRILY
| Q4 25 | $1.4B | $1.7B | ||
| Q3 25 | $1.4B | $1.7B | ||
| Q2 25 | $1.4B | $1.5B | ||
| Q1 25 | $1.3B | $1.5B | ||
| Q4 24 | $1.3B | $1.8B | ||
| Q3 24 | $966.3M | $2.2B | ||
| Q2 24 | $982.2M | $3.2B | ||
| Q1 24 | $979.0M | $5.0B |
负债/权益比PAHCRILY
| Q4 25 | 1.88× | — | ||
| Q3 25 | 2.01× | — | ||
| Q2 25 | 2.21× | — | ||
| Q1 25 | 2.39× | — | ||
| Q4 24 | 2.59× | — | ||
| Q3 24 | 1.14× | — | ||
| Q2 24 | 1.22× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.4M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $8.3M | — |
| 自由现金流率自由现金流/营收 | 2.2% | — |
| 资本支出强度资本支出/营收 | 3.0% | — |
| 现金转化率经营现金流/净利润 | 0.70× | 0.29× |
| 过去12个月自由现金流最近4个季度 | $47.3M | — |
8季度趋势，按日历期对齐
经营现金流PAHCRILY
| Q4 25 | $19.4M | $26.2M | ||
| Q3 25 | $9.3M | $-60.6M | ||
| Q2 25 | $21.3M | $-25.6M | ||
| Q1 25 | $43.2M | $184.0K | ||
| Q4 24 | $3.1M | $-2.7M | ||
| Q3 24 | $12.6M | $19.5M | ||
| Q2 24 | $28.4M | $111.5M | ||
| Q1 24 | $11.4M | $135.4M |
自由现金流PAHCRILY
| Q4 25 | $8.3M | — | ||
| Q3 25 | $-4.5M | — | ||
| Q2 25 | $8.1M | — | ||
| Q1 25 | $35.4M | — | ||
| Q4 24 | $-4.7M | — | ||
| Q3 24 | $3.0M | — | ||
| Q2 24 | $15.4M | — | ||
| Q1 24 | $1.7M | — |
自由现金流率PAHCRILY
| Q4 25 | 2.2% | — | ||
| Q3 25 | -1.2% | — | ||
| Q2 25 | 2.1% | — | ||
| Q1 25 | 10.2% | — | ||
| Q4 24 | -1.5% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 5.6% | — | ||
| Q1 24 | 0.6% | — |
资本支出强度PAHCRILY
| Q4 25 | 3.0% | — | ||
| Q3 25 | 3.8% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 4.8% | — | ||
| Q1 24 | 3.7% | — |
现金转化率PAHCRILY
| Q4 25 | 0.70× | 0.29× | ||
| Q3 25 | 0.35× | -0.66× | ||
| Q2 25 | 1.24× | -0.18× | ||
| Q1 25 | 2.07× | — | ||
| Q4 24 | 0.97× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 37.80× | — | ||
| Q1 24 | 1.36× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
